UroGen Pharma Ltd. (NASDAQ:URGN)
| Market Cap | 1.71B+134.8% |
| Revenue (ttm) | 188.73M+100.3% |
| Net Income | -97.64M+37.0% |
| EPS | -1.98+40.4% |
| Shares Out | 48.72M |
| PE Ratio | n/a |
| Forward PE | 13.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 778,523 |
| Open | 39.93 |
| Previous Close | 40.70 |
| Day's Range | 34.18 - 40.05 |
| 52-Week Range | 15.86 - 50.81 |
| Beta | 1.58 |
| Analysts | Buy |
| Price Target | 56.60(+61.39%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$URGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in URGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by URGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
URGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
URGN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Accruals | $29.92M | 76.09% |
| Balance | $9.40M | 23.91% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New URGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to URGN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in URGN
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $46.09M |
| IWOiShares Russell 2000 Growth ETF | $14.26M |
| IBBiShares Biotechnology ETF | $13.01M |
| VTWOVanguard Russell 2000 ETF | $10.55M |
| FESMFidelity Enhanced Small Cap ETF | $8.72M |
| SPDWState Street SPDR Portfolio Developed World ex-US ETF | $7.72M |
Estimated from each fund’s disclosed top holdings × AUM
URGN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from URGN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score